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December 13/20, 2011:2696–702treated with doxorubicin and trastuzumab, while at the same time,
preventing any detrimental side effects on cardiac health.
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Cardiovascular Risk Assessment of
Liver Transplantation Candidates
We read with great interest the report by Raval et al. (1) on
cardiovascular risk assessment of candidates for liver transplanta-tion (LT) and would like to congratulate the investigators on a
comprehensive and thorough review.
We disagree, however, with a comment made in the section on
heart failure and cardiomyopathy and the evidence provided in the
report. The investigators, quite rightly, recommend that all pa-
tients undergo pre-operative transthoracic echocardiography, a
practice routinely undertaken at LT centers. They then state that
patients with left ventricular ejection fractions as low as 10% have
successfully undergone LT after aggressive medical management,
citing a Canadian case series (2). We believe this deserves further
analysis. The publication describes 4 patients with end-stage
hypertrophic, dilative, and ischemic cardiomyopathy who under-
went combined cardiac transplantation and LT on cardiopulmo-
nary bypass. All patients were highly symptomatic, with New York
Heart Association functional class III or IV heart failure, and 3 had
congestive cirrhosis due to right ventricular failure. It appears as if
the primary indication for transplantation was cardiac, but heart
transplantation alone was not possible, because of end-stage liver
disease. We believe that the term “aggressive medical manage-
ment” is misleading in this context and does not appropriately
describe the complexity of the procedures performed. We strongly
believe that severe and symptomatic heart failure is an absolute
contraindication for LT, unless a combined heart and liver
transplantation procedure is considered.
In the section on recommendations for assessment, the role of
cardiopulmonary exercise testing, in particular the assessment of
aerobic capacity, was not commented on. The most sensitive index
of aerobic capacity is oxygen consumption at peak exercise (peak
VO2). Evaluation of peak VO2 is increasingly used at LT centers as
part of the routine assessment. Dharancy et al. (3) demonstrated
that a peak VO2 of 60% was associated with reduced 1-year
urvival in patients listed for LT. The predictive ability of peak
O2 was more evident in patients with Model for End-Stage Liver
isease scores 17.
In summary, severe left ventricular failure remains in our view
n absolute contraindication for LT despite aggressive medical
anagement. Dynamic cardiopulmonary testing and assessment of
erobic capacity provides important prognostic information and
hould be considered in all patients undergoing elective LT
ssessment.
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Reply
We appreciate the comments of Dr. Joshi and colleagues regarding
our report on the cardiovascular risk assessment of candidates for
liver transplantation (1).
We agree that liver transplantation in patients with severe left
ventricular systolic dysfunction carries a higher risk for cardiovas-
cular complications and mortality. These patients should be
thoroughly evaluated, as we have described, and would benefit
from referral to higher volume transplantation centers with expe-
rience in caring for such patients. As noted in our report, and by
Joshi et al., there have been case reports of successful transplanta-
tion in such patients, often requiring combined liver and heart
transplantation (2). Several potential etiologies of systolic dysfunc-
tion in patients with end-stage liver disease have been described,
and some may be reversible (3,4). Therefore, we do not consider
severe systolic dysfunction to be an absolute contraindication to
liver transplantation. However, liver transplantation in this patient
type should be undertaken only at centers with advanced heart
failure programs.
With regard to the utility of the measurement of oxygen
consumption at peak exercise to assess aerobic capacity, this is
certainly another piece of information that can be added to the
cardiologist’s armamentarium when performing a cardiovascular
risk assessment of a liver transplantation candidate. In a multivar-
iate analysis, it was associated with 1-year survival and was also
associated with post-operative complications in sicker patients (5).
Although we do not believe that this should be a sole reason for
exclusion for liver transplantation candidacy, we agree that it may
aid in assessing cardiovascular risk.
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The Role of Platelet Function
Testing and Genotyping
in the Stented Patient
Treated With Clopidogrel
We read with interest the study of Campo et al. (1). Their
observation that P2Y12 reaction units (PRU) decreased at 1 month
compared to baseline in patients receiving clopidogrel undergoing
percutaneous coronary intervention (PCI) is similar to our report
in 2003 (2), where 30% of patients were resistant at 1 and 5 days
post-PCI, and 15% were resistant at 30 days. Similar observation
of lower prevalence of 30-day high platelet reactivity compared to
12 to 24 h post-stenting was also reported recently (3). We further
presented similar PRU levels at 24 h after 600 mg loading and just
before the last maintenance dose at 6 weeks (4). Mean PRUs at 8 h
after last maintenance dose decreased by 25. These findings
indicate the “booster” effect of the last maintenance dose by new
active metabolite generation. Therefore, clopidogrel response is
significantly influenced by measured time after clopidogrel admin-
istration even during the maintenance phase. In the study by
Campo et al. (1), a decrease in PRU levels at 1 month may be
partially related to measured time (25 PRU in stable patients).
However, Campo et al. (1) did not mention the timing of
measurements with respect to the last dose administration.
Another important issue is that the post-PCI event occurrence
reported by Campo et al. (1) is relatively discordant with most
PCI-related studies demonstrating more frequent events within 30
to 60 days post-PCI. Interestingly, the first ischemic event in
Campo et al. (1) occurred at 50 days post-PCI (estimated from
Fig. 3 of Campo et al. [1]).
In multivariate analysis, CYP2C19*17 variant and 30-day PRU
together were independent determinants of bleeding, implicating
that CYP2C19*17 effect on bleeding may be independent of
clopidogrel response, which requires further explanation. Although
platelet function testing and genotyping may play complementary
roles in tailoring antiplatelet therapy, numerous clinical factors
including drug-drug interaction may influence the magnitude of
platelet reactivity and clinical outcomes. In the future, a compre-
hensive algorithm including clinical as well as laboratory findings
may optimize outcomes in the era of potent P2Y12 inhibitors.
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